These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 15238139)

  • 1. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
    Lai FP; Cole-Sinclair M; Cheng WJ; Quinn JM; Gillespie MT; Sentry JW; Schneider HG
    Br J Haematol; 2004 Jul; 126(2):192-201. PubMed ID: 15238139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
    Farrugia AN; Atkins GJ; To LB; Pan B; Horvath N; Kostakis P; Findlay DM; Bardy P; Zannettino AC
    Cancer Res; 2003 Sep; 63(17):5438-45. PubMed ID: 14500379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
    Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
    J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
    Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
    Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
    Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
    J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
    Suzuki T; Suda N; Ohyama K
    J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
    Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
    Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption.
    Heinrich J; Bsoul S; Barnes J; Woodruff K; Abboud S
    Arch Oral Biol; 2005 Oct; 50(10):897-908. PubMed ID: 16137499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
    J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.
    Heider U; Zavrski I; Jakob C; Bängeroth K; Fleissner C; Langelotz C; Possinger K; Hofbauer LC; Viereck V; Sezer O
    J Cancer Res Clin Oncol; 2004 Aug; 130(8):469-74. PubMed ID: 15205949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
    J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.
    Pearse RN; Sordillo EM; Yaccoby S; Wong BR; Liau DF; Colman N; Michaeli J; Epstein J; Choi Y
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11581-6. PubMed ID: 11562486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.